You are reading one round. Fundz also knows which of your own LinkedIn connections can open this account.See it live →
French biotech AbTx secures €1.7M seed funding to advance miniaturized cancer antibodies using its Therano-Stick platform.
PRIVATESep 18, 2026•about 3 hours ago
Amount Raised
€1.7 Million
Round Type
Seed
FranceBiotechnology
Description
AbTx, a French biotech startup established in 2024, secured €1.7 million in seed funding to advance its Therano-Stick platform for precision cancer therapies. The platform uses enzymatic bio-conjugation to create miniaturized antibody-drug conjugates targeting solid tumors resistant to standard treatments. The funding will support clinical development and validation of the company's proprietary manufacturing process. AbTx recently won the prestigious i-Lab award, validating its oncology approach.
Company Information
Company
AbTx
Location
France
About
AbTx is a French biotech startup established in 2024 that develops precision therapies for solid tumors using their proprietary Therano-Stick platform. The company creates miniaturized antibody-drug conjugates (FDCs) through enzymatic bio-conjugation technology. AbTx recently secured €1.7 million in seed funding and won the prestigious i-Lab award for their oncology platform.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment AbTx raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
FranceBiotechnology